Litigation

Recent Posts

6th Circuit Panel Affirms Most Darvon/Darvocet/Propoxyphene Claims Are Preempted
Posted on 30 Jun 2014 by Tom Moylan

CINCINNATI — (Mealey’s) The Sixth Circuit U.S. Court of Appeals on June 27 affirmed dismissal of 67 of 68 Darvon/Darvocet/ propoxyphene multidistrict litigation cases, finding that the plaintiffs either failed to properly plead their claims... Read More

Tags: drugs , and Propoxyphene Products Liability Litigation , preemption , Sixth Circuit U.S. Court of Appeals , Darvon , In re: Darvocet , Inc. v. Bartlett , drug design defect preemption , Darvocet , Yanise Germain , Xanodyne Pharmaceuticals Inc. , Litigation , Inc. , multidistrict litigation , propoxyphene , generic drug manufacturers , Eli Lilly and Co. , usa , MDL , torts , Mutual Pharmacy Co. , et al. v. Teva Pharmaceuticals

N.J. Risperdal Jury Finds Diabetes Warning Lacking, But Drug Didn't Cause Disease
Posted on 17 Feb 2012 by Tom Moylan

NEW BRUNSWICK, N.J. - (Mealey's) A Risperdal personal injury trial ended Feb. 16 in a defense verdict for Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. after a New Jersey state court jury found that Janssen failed to warn about the... Read More

Tags: Gary D. Skala , drugs , Risperdal , et al. , Johnson , personal injury , AstraZeneca , New Jersey , Gary D. Skala v. Johnson &amp , Litigation , amp , mass tort , Eli Lilly and Co. , Zyprexa , verdict , diabetes , Seroquel , Janssen Pharmaceuticals , Johnson &amp , antipsychotic drug

No New Trial In Actos MDL Bellwether Case, But Punitives Are Cut From $9 Billion To $36 Million
Posted on 29 Oct 2014 by Tom Moylan

LAFAYETTE, La. — (Mealey’s) Takeda Pharmaceutical Co. Ltd. and Eli Lilly and Co. will not get a new trial in the first Actos bladder cancer multidistrict litigation bellwether case, but a Louisiana federal judge on Oct. 27 reduced the $9 billion... Read More

Tags: diabetes drug , Terrence Allen v. Takeda Pharmaceuticals North America , punitive damages , In Re: Actos [Pioglitazone] Products Liability Litigation , Actos , product liability , Terrence Allen , bladder cancer , MDL Docket No. 2299 , Louisiana , Litigation , multidistrict litigation , Eli Lilly and Co. , verdict , torts , Takeda Pharmaceutical

6 Third-Party Payers Settle Zyprexa Claims For $4.5Million After Class Vacated
Posted on 13 Jan 2012 by Tom Moylan

BROOKLYN, N.Y. - (Mealey's) The Zyprexa multidistrict litigation judge on Jan. 12 approved a $4.5 million settlement between Eli Lilly and Co. and six third-party payers who had their Racketeer Influence and Corrupt Organizations Act (RICO) class... Read More

Tags: In Re: Zyprexa Products Liability Litigation , RICO , Racketeer Influenced and Corrupt Organizations Act , class action , UFCW Local 1776 v. Eli Lilly and Company , Litigation , multidistrict litigation , Settlement , Eli Lilly and Co. , Zyprexa

97 Federal Cases Alleging Cancer From Diabetes Drugs Centralized In MDL
Posted on 27 Aug 2013 by Tom Moylan

WASHINGTON, D.C. — (Mealey’s) Ninety-seven federal lawsuits in which plaintiffs allege that three incretin-based diabetes drugs caused their pancreatic cancer were centralized Aug. 26 by a federal judicial panel into a multidistrict litigation... Read More

Tags: Novo Nordisk Inc. , California , Januvia , Victoza , Byetta , U.S. District Court for the Southern District of California , diabetes drugs , pancreatic cancer , Litigation , multidistrict litigation , Merck Sharp & Dohme Corp. , Eli Lilly and Co. , In Re: Incretin Mimetics Products Liability Litigation , Amylin Pharmaceuticals , MDL